1303994-09-3

Basic information

• Product Name: (RS)-α-Methyl-4-carboxyphenylglycinedisodiumsalt
• Synonyms: (RS)-MCPG disodium salt;(RS)-α-Methyl-4-carboxyphenylglycinedisodiumsalt;Benzeneacetic acid, α-amino-4-carboxy-α-methyl-, sodium salt (1:1)
• CAS NO: 1303994-09-3
• Molecular Formula: C10H9NNa2O4
• Molecular Weight: 233.2
• Mol File: 1303994-09-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Storage Temp.: Store at RT
• CAS DataBase Reference: (RS)-α-Methyl-4-carboxyphenylglycinedisodiumsalt(CAS DataBase Reference)
• NIST Chemistry Reference: (RS)-α-Methyl-4-carboxyphenylglycinedisodiumsalt(1303994-09-3)
• EPA Substance Registry System: (RS)-α-Methyl-4-carboxyphenylglycinedisodiumsalt(1303994-09-3)

Safety Data

• Hazardous Substances Data: 1303994-09-3(Hazardous Substances Data)

Usage

Description

(RS)-α-Methyl-4-carboxyphenylglycinedisodiumsalt, also known as (RS)-MCPG Disodium Salt, is a synthetic compound that acts as a non-selective group I/II metabotropic glutamate receptor antagonist. It is characterized by its ability to block the activity of metabotropic glutamate receptors, which play a crucial role in the regulation of synaptic transmission and neuronal excitability.

Uses

Used in Pharmaceutical Industry:
(RS)-α-Methyl-4-carboxyphenylglycinedisodiumsalt is used as a research chemical for the development of drugs targeting neurological disorders. Its antagonistic properties allow researchers to study the role of metabotropic glutamate receptors in various conditions, such as anxiety, depression, and neurodegenerative diseases.
Used in Neuroscience Research:
In the field of neuroscience, (RS)-α-Methyl-4-carboxyphenylglycinedisodiumsalt serves as a valuable tool for investigating the function and mechanisms of metabotropic glutamate receptors. By blocking these receptors, researchers can gain insights into their involvement in synaptic plasticity, learning, and memory processes.
Used in Drug Discovery:
(RS)-α-Methyl-4-carboxyphenylglycinedisodiumsalt is utilized in drug discovery efforts to identify potential therapeutic agents that can modulate the activity of metabotropic glutamate receptors. This can lead to the development of novel treatments for a range of neurological and psychiatric conditions.